My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036)
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting. (10:17)
Tag Archives: Advanced NSCLC
Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB). (9:39)
Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB). (13:06)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (<1%) Tumor PD-L1 Expression (BMIC-033)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (<1%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset. (6:31)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset. (6:15)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients. (7:57)
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advanced non-squamous NSCLC with any PD-L1 expression. (13:05)
Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise. (5:02)
New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)
Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced NSCLC, along with the clinical implications of various options based on these observations. (11:33)
T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed strongest benefit of atezo in those with T effector gene signature high expression or high PD-L1. (10:19)